Table I.

Negative correlation of AnxA6 expression with various types of cancer.

Tumor type	AnxA6 expression pattern	Implication	Ref.
Melanoma	Low expression levels in melanoma malignancy	AnxA6 acts as a tumor suppressor in melanoma	(26)
Epithelial carcinoma	No expression in A431 cells	Overexpression of AnxA6 leads to growth and tumor suppression effects in A431 cells	(23,27–29)
BC	Low expression levels in invasive ductal carcinoma and mucous adenocarcinoma tissues	AnxA6 is a potential marker for detection of BC and prediction of survival	(28,34,35)
GC	Low expression levels in GC cells and tissues	AnxA6 is a potential suppressor of GC	(30)
PCa	Low expression levels in localized PCa tissues and reduced during PCa progression	AnxA6 inversely correlates with PCa progression	(31,32)
CML	Low expression levels in FDCP-Mix cells on long term exposure to Bcr-Abl PTK	AnxA6 contributes to CML progression regulated by Bcr-Abl PTK	(37)

AnxA6, annexin A6; BC, breast cancer; GC, gastric cancer; PCa, prostate cancer; CML, chronic myeloid leukemia; FDCP, factor-dependent cell progenitors; Bcr, breakpoint cluster region; Abl, Abelson murine leukemia viral oncogene homolog 1; PTK, protein tyrosine kinase.